Chronic dopamine receptor stimulation using bromocriptine: failure to modify thyroid function.
Administration of 2.5 mg bromocriptine (Parlodel), a dopamine agonist, on two occasions to six normal volunteers did not alter the plasma TSH response to an i.v. injection of 100 micrograms TRH, but significantly (P less than 0.01) blunted it after 200 micrograms. Chronic bromocriptine treatment (7.5--50 mg/day) of fifteen acromegalic subjects failed to influence basal plasma TSH or the response pattern to 200 micrograms TRH. The thyroxine Binding Index (TBI) and the levels of T3 and T4 were not modified by treatment. These results indicate that chronic dopaminergic therapy with bromocriptine does not alter thyroid function.
D000172:Acromegaly / Q000188:drug therapy; D001971:Bromocriptine / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D011954:Receptors, Dopamine / Q000187:drug effects*; D013961:Thyroid Gland / Q000502:physiology*; D013972:Thyrotropin / Q000097:blood; D013973:Thyrotropin-Releasing Hormone
D011954:Receptors, Dopamine; D001971:Bromocriptine; D013973:Thyrotropin-Releasing Hormone; D013972:Thyrotropin